Human Parvovirus B19 IgG Lateral flow dipstick kit 4472

$487.00

Summary

Mikrogen diagnostik lateral flow device (dipstick) for research use (RUO)
Human Parvovirus B19 IgG Lateral flow dipstick kit 4472
Suitable for IgG detection
Ready-to-use
20 tests

SKU: 4472 Category: kits Tags: IgG, Lateral Flow Dipsticks, Parvovirus B19

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Human Parvovirus B19 IgG
species reactivity	Human Parvovirus B19
applications	Lateral flow (dipstick)
assay type	Indirect & qualitative
available sizes	20 test kits

Human Parvovirus B19 IgG Lateral flow dipstick kit 4472

Assay type
Sandwich assay, lateral flow (dipstick)

Research area
Infectious Disease

Sample type
Serum, plasma, whole blood

Components

10X Wash Buffer	100 mL
TMB Substrate	40 mL
Milk Powder	5 g
Instructions for Use	1 Each
Evaluation Form	1 Each
Test Strips	2 kits of [2 Vials x 10 Each]
Anti-Human IgG Conjugate	500 ?L
Positive Control	140 ?L
Negative Control	140 ?L

Storage
Store at 2-8°C.

Additional information
Mikrogen recomLine Parvovirus B19 Test

The Mikrogen recomLine Parvovirus B19 tests allow an indication of the time of infection due to the reactivity patterns of the recombinant antigens and the possibility to detect avidity determination of the IgG antibodies.

The determination of antibodies against the NS-1 antigen can be helpful in clarifying persistent parvovirus B19 infections. By using VP-2 particles, a presentation of conformational epitopes to the otherwise presented linear epitopes is achieved.

Advantages

Separate detection of IgG and IgM antibodies with antibody class control on the test strip.
Band pattern and avidity determination allow conclusions on infection status.
Parvovirus B19 infections during the last 4 weeks can be reliably excluded.
Excellent diagnostic quality due to internal controls and the use of VP2 particles.
Easy and clear interpretation, featuring easy-to-read banding patterns.
Partial and full automation, software-based evaluation (recomScan), and integration with the laboratory information system are possible.
Highest sensitivity and specificity due to the use of recombinant antigens.

Bands

Antigen	Abbreviation	Size (kDa)
Main capsid antigen (conformational epitopes)	VP-2p	65
N-terminal half of the structural proteins VP-1 and VP-2	VP-N	60
VP-1 specific segment (differentiation from VP-2)	VP-1S	31
Main capsid antigen (linear epitopes)	VP-2r	56
C-terminal half of the structural proteins VP-1 and VP-2	VP-C	42
Non-structural protein NS-1	NS-1	75

target relevance
Organism Parvovirus B19
Structure and strains Human parvovirus B19, generally referred to as B19 virus (B19V), parvovirus B19 or sometimes erythrovirus B19, is the first (and until 2005 the only) known human virus in the family Parvoviridae, genus Erythroparvovirus; it measures only 23 26 nm in diameter. Human parvovirus b19 is a below-species classification of Erythroparvovirus primate1. The name is derived from Latin parvum, meaning small, reflecting the fact that B19 ranks among the smallest DNA viruses. B19 virus is most known for causing disease in the pediatric population; however, it can also affect adults. It is the classic cause of the childhood rash called fifth disease or erythema infectiosum, or "slapped cheek syndrome".
Disease With a diameter of 18-26 nm, the worldwide distributed Parvovirus B19 belongs to the smallest human pathogens. Its capsid is made up of 95% of the structural protein VP2. The remaining 5% consists of VP1. In many cases, Parvovirus B19 infections remain clinically asymptomatic. Infected children may develop erythema infectiosum, also named fifth disease. After an incubation period of four to 14 days garland-shaped exanthemas spread from the face downwards. The rash, in adults possibly accompanied by arthralgia in the small joints, may last for up to three weeks. Current studies in Germany indicate that 10-20% of children under three years of age have already had an infection with the virus. In adults, the seroprevalence increases to 70%. In pregnant women with primary Parvovirus B19 infection the virus is transmitted to the fetus and may lead to severe complications. In general, the regular course of an infection is limited by the synthesis of neutralizing antibodies. In immunosuppressed patients or patients with chronic haemolytic anaemia, infection may elicit severe clinical consequences with aplastic crisis, which can have fatal consequences.
Detection and diagnosis As a consequence of the variable clinical symptoms which may be associated with Parvovirus B19 infection, a clinical diagnosis should be supported by the demonstration of virus specific antibodies.

Data

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.